<DOC>
	<DOCNO>NCT00132808</DOCNO>
	<brief_summary>Osteoporosis prevention important patient osteopenia ( low bone density ) . This study test safety efficacy zoledronic acid patient diagnose osteopenia .</brief_summary>
	<brief_title>Zoledronic Acid Prevention Bone Loss Postmenopausal Women With Osteopenia , 45 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal Greater equal 45 year age Osteopenia ( lumbar spine bone mineral density [ BMD ] Tscore 1.0 2.5 , BMD Tscore &gt; 2.5 femoral neck ) Patients one Grade 1 vertebral fracture ( per Genant method ; patient one Grade 1 vertebral fracture eligible participate ) Patients Grade 2 3 vertebral fracture ( per Genant method ) Patients 25 ( OH ) vitamin D level less 15 ng/mL prior randomization Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Postmenopausal osteoporosis</keyword>
	<keyword>osteopenia</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>Osteopenia ( osteoporosis prevention )</keyword>
</DOC>